Head-To-Head Contrast: Oncocyte (IMDX) versus Its Competitors

Oncocyte (NASDAQ:IMDX) is one of 853 publicly-traded companies in the “Biotechnology” industry, but how does it contrast to its rivals? We will compare Oncocyte to similar companies based on the strength of its earnings, risk, institutional ownership, analyst recommendations, valuation, dividends and profitability.

Profitability

This table compares Oncocyte and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Oncocyte	-2,955.63%	N/A	-107.52%
Oncocyte Competitors	-9,415.99%	-127.07%	-33.00%

Valuation & Earnings

This table compares Oncocyte and its rivals gross revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Oncocyte	$4.05 million	-$50.22 million	-2.63
Oncocyte Competitors	$685.14 million	$9.20 million	-10.10

Oncocyte’s rivals have higher revenue and earnings than Oncocyte. Oncocyte is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Institutional and Insider Ownership

55.3% of Oncocyte shares are owned by institutional investors. Comparatively, 48.1% of shares of all “Biotechnology” companies are owned by institutional investors. 2.2% of Oncocyte shares are owned by company insiders. Comparatively, 13.1% of shares of all “Biotechnology” companies are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of current ratings and target prices for Oncocyte and its rivals, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oncocyte	1	0	2	0	2.33
Oncocyte Competitors	9557	14958	44880	1526	2.54

Oncocyte presently has a consensus target price of $10.50, indicating a potential upside of 167.86%. As a group, “Biotechnology” companies have a potential upside of 63.54%. Given Oncocyte’s higher possible upside, equities research analysts plainly believe Oncocyte is more favorable than its rivals.

Volatility and Risk

Oncocyte has a beta of 1.8, meaning that its share price is 80% more volatile than the S&P 500. Comparatively, Oncocyte’s rivals have a beta of 1.11, meaning that their average share price is 11% more volatile than the S&P 500.

Summary

Oncocyte beats its rivals on 7 of the 13 factors compared.

Oncocyte Company Profile

OncoCyte Corporation, a molecular diagnostics company, researches, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early-stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay. It also provides biomarker discovery testing, assay design and development, and clinical trial support services, as well as various biomarker tests for pharmaceutical companies. The company has a collaboration agreement with Life Technologies Corporation to develop and collaborate in the commercialization of Oncomine Comprehensive Assay Plus and Determa IO assay for use with Ion Torrent Genexus integrated sequencer and purification system. OncoCyte Corporation was incorporated in 2009 and is based in Irvine, California.